Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of Cavacini, Lisa

The major focus of my laboratory research is in the area of immunoregulation of infectious disease, cancer and autoimmune disease. Human monoclonal antibodies are characterized to study the humoral immune response in these disorders. . In addition, the laboratory is interested in developing active and passive forms of immunotherapy for the treatment of these disease areas. Not only do we generate new human monoclonal antibodies for our studies, but also for a large number of laboratories throughout the world for research on infectious diseases, cancer and autoimmune disease. We collaborate with Drs. Greiner, Brehm and Luban here at UMMS and Dr. Leonard Schultz at Jackson Laboratories on humanized mouse models for the generation of human monoclonal antibodies and as models for passive immunotherapy for bacterial or viral infections. The laboratory has also been involved in pharmacokinetic and pharmacodynamic studies of IgG and IgA human monoclonal antibodies, in several bacterial and viral infections. To further develop Dr. Cavacini’s background in mucosal immunology, included in this work is structural modeling of antibody/antigen interactions to improve the design of immunotherapeutic antibodies and development of a platform for production of dimeric and secretory IgA. These leading activities in IgA immunotherapy are currently being translated into clinical development of mucosal IgA molecules for prevention or treatment of two diverse bacterial infections. In addition to Dr. Cavacini’s current work on immunoprophylaxis for mucosal bacterial infections (e.g. Enterotoxigenic Escherichia coli,, Bordetella pertussis, Klebsiella pneumonia), she is also inventor of two human monoclonal antibodies against Staphylococcus aureus and Pseudomonas aeruginosa. Dr. Cavacini also contributes to programs for Lyme Disease and other emerging pathogens. Most recently, this has been to generate reagents and establish assays for screening novel drug candidates for immunoprophylaxis or treatment of COVID-19. Our initial screen of MassBiologics’ existing panel of SARS-CoVspecific antibodies resulted in Mabs with ELISA binding activity to the receptor binding domain of the SARS-CoV-2 Spike protein.  We have moved on to nanobody discovery for broadly neutralizing antibodies against all variants of concern and interest.  The expertise at MassBiologics, particularly in the areas of Discovery and Process Development, has allowed rapid production of SARS CoV-2 proteins (including several spike proteins and N protein) and human antibodies and nanobodies , contributing to the evaluation and development of therapeutics and diagnostics.

One or more keywords matched the following items that are connected to Cavacini, Lisa
Item TypeName
Concept Antibodies, Neutralizing
Academic Article Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.
Academic Article Neutralization of HIV by milk expressed antibody.
Academic Article Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
Academic Article V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Academic Article Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.
Academic Article Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition.
Academic Article Human Anti-HIV-1 gp120 Monoclonal Antibodies with Neutralizing Activity Cloned from Humanized Mice Infected with HIV-1.
Academic Article A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.
Academic Article Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design.
Academic Article Human genital antibody-mediated inhibition of Chlamydia trachomatis infection and evidence for ompA genotype-specific neutralization.
Search Criteria
  • Antibodies Neutralizing